1. ？CROCI D O, SALATINO M. Tumor immune escape mechanisms that operate during metastasis[J]. Curr Pharm Biotechnol, 2011, 12(11):1923-1936.
[2]
2. ENGERS R, GABBERT H E. Mechanisms of tumor metastasis:cell biological aspects and clinical implications[J]. J Cancer Res Clin Oncol, 2000, 126(12):682-692.
[3]
3. CAIRNS R A, KHOKHA R, HILL R P. Molecular mechanisms of tumor invasion and metastasis:an integrated view[J]. Curr Mol Med, 2003, 3(7):659-671.
[4]
4. PRESSIANI T, BONI C, RIMASSA L, et al. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma:a prospective feasibility analysis[J]. Ann Oncol, 2013, 24(2):406-411.
[5]
5. BISSELL M J, RADISKY D C, RIZKI A, et al. The organizing principle:microenvironmental influences in the normal and malignant breast[J]. Differentiation, 2002, 70(9/10):537-546.
[6]
6. TOI M, INADA K, SUZUKI H, et al. Tumor angiogenesis in breast cancer:its importance as a prognostic indicator and the association with vascular endothelial growth factor expression[J]. Breast Cancer Res Treat, 1995, 36(2):193-204.
[7]
7. MBEUNKUI F, JOHANN D J. Cancer and the tumor microenvironment:a review of an essential relationship[J]. Cancer Chemother Pharmacol, 2009, 63(4):571-582.
[8]
8. LEONARDI G C, CANDIDO S, CERVELLO M, et al. The tumor microenvironment in hepatocellular carcinoma (review)[J]. Int J Oncol, 2012, 40(6):1733-1747.
[9]
9. LOGES S, MAZZONE M, HOHENSINNER P, et al. Silencing or fueling metastasis with VEGF inhibitors:antiangiogenesis revisited[J]. Cancer Cell, 2009, 15(3):167-170.
[10]
10. NYBERG P, XIE L, KALLURI R. Endogenous inhibitors of angiogenesis[J]. Cancer Res, 2005, 65(10):3967-3979.
[11]
11. GARCIA A, KANDEL J J. Notch:a key regulator of tumor angiogenesis and metastasis[J]. Histol Histopathol, 2012, 27(2):151-156.
[12]
12. PRIOR B M, YANG H T, TERJUNG R L. What makes vessels grow with exercise training?[J]. J Appl Physiol, 2004, 97(3):1119-1128.
[13]
13. GOMES F G, NEDEL F, ALVES A M, et al. Tumor angiogenesis and lymphangiogenesis:tumor/endothelial crosstalk and cellular/microenvironmental signaling mechanisms[J]. Life Sci, 2013, 92(2):101-107.
[14]
14. KHODAREV N N, YU J, LABAY E, et al. Tumour-endothelium interactions in co-culture:coordinated changes of gene expression profiles and phenotypic properties of endothelial cells[J]. J Cell Sci, 2003, 116(Pt 6):1013-1022.
[15]
15. CABRERA R, NELSON D R. Review article:the management of hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2010, 31(4):461-476.
[16]
16. LIN Weiyang, HSU W H. Tumor-to-tumor metastasis:maxillary sinus adenoid cystic carcinoma metastasizing to double primary lung adenocarcinoma[J]. Ann Thorac Surg, 2010, 90(4):e59-e61.
[17]
17. SEAVEY M M, MACIAG P C, AL-RAWI N, et al. An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis Cancer vaccine for the treatment of primary and metastatic Her-2/neu+breast tumors in a mouse model[J]. J Immunol, 2009, 182(9):5537-5546.
[18]
18. CHEN Zhijian, HTAY A, DOS SANTOS W, et al. In vitro angiogenesis by human umbilical vein endothelial cells(HUVEC)induced by three-dimensional co-culture with glioblastoma cells[J]. J Neurooncol, 2009, 92(2):121-128.
[19]
19. YOSHIJI H, KURIYAMA S, HICKLIN D J, et al. The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model[J]. Hepatology, 2001, 33(4):841-847.
[20]
20. SHIBUYA M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis[J]. J Biochem Mol Biol, 2006, 39(5):469-478.
[21]
21. HICKLIN D J, ELLIS L M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis[J]. J Clin Oncol, 2005, 23(5):1011-1027.
